使用聚醚醚酮(PEEK)聚合物植入物行椎体增强术治疗分离型(Magerl A2)椎体骨折后疼痛减轻与高度恢复的评估:一项前瞻性长期非随机研究
这项前瞻性非随机研究评估了21处疼痛性分离型椎体骨折(20例患者)经皮PEEK植入物椎体增强术的安全性和长期疗效。术后第1天疼痛评分较基线下降7.50个NVS单位(p<0.001),椎体最小和最大高度分别增加56.58%和13.7%(p<0.001),2年随访期间疼痛缓解和高度恢复均保持统计学显著(p<0.001),无重大临床并发症。作者认为A2型胸腰椎骨折可成功采用PEEK植入物辅助椎体增强术治疗,但需更大样本随机研究确认。
要点
- PEEK植入物椎体增强术治疗A2型胸腰椎骨折,术后第1天疼痛NVS评分较基线下降7.50分(p<0.001)。
- 术后椎体最小高度增加56.58%、最大高度增加13.7%(p<0.001),2年随访期间高度恢复保持显著。
- 所有病例植入物定位成功,未观察到重大临床并发症。
核心结论
- A2型Magerl胸椎或腰椎骨折可成功采用PEEK植入物辅助椎体增强术治疗,疼痛减轻和高度恢复效果在2年随访期间持续存在;作者认为需更大样本随机研究确认该技术有效性。
研究设计与样本
- 前瞻性非随机研究,纳入20例患者共21处疼痛性分离型椎体骨折(14例女性、6例男性,平均年龄72.80±10.991岁),在透视引导下经皮行PEEK装置椎体增强术,术前及术后6、12、24个月用数字视觉量表(NVS)问卷评估疼痛,采用CT和X线测量骨折层面最小头尾径及骨折椎体中部最大头尾径。
关键影像表现/征象
- 所有病例均实现植入物成功定位。
- 术后骨折层面椎体最小头尾径增加56.58%,骨折椎体中部最大头尾径增加13.7%(p<0.001)。
- 未观察到重大临床并发症。
诊断标准与关键数值
- 疼痛评估采用数字视觉量表(NVS)问卷,基线平均疼痛评分8.69±1.138,术后第1天平均1.19±1.424,下降7.50个NVS单位(p<0.001)。
- 影像测量指标为骨折层面最小头尾径和骨折椎体中部最大头尾径,术后分别增加56.58%和13.7%(p<0.001)。
- 随访期疼痛缓解和高度恢复均保持统计学显著(p<0.001)。
临床应用与阅片要点
- 对A2型Magerl胸腰椎分离型骨折,可经透视引导经皮置入PEEK装置行椎体增强术,术后用CT和X线测量骨折层面最小头尾径及椎体中部最大头尾径以评估高度恢复。
- 术后采用NVS问卷在6、12、24个月随访评估疼痛变化。
局限性
- 作者指出需开展更大样本量的随机研究以确认该技术的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purposes of the study were to evaluate the safety and long-term efficacy of augmented vertebroplasty using a polyether ether ketone (PEEK) implant, for the treatment of lumbar or thoracic vertebral fractures (A2 according to the Magerl's AO classification) and to analyze pain reduction, height restoration, and complications during a 2-year follow-up period.
METHODS: Prospective non-randomized evaluation was performed for 21 painful split vertebral fractures (20 patients, 14 females, 6 males; mean age 72.80 ± 10.991) treated with percutaneous vertebral augmentation using a PEEK device, under fluoroscopic guidance. Pain before the procedure and after 6, 12, and 24 months was evaluated using a numeric visual scale (NVS) questionnaire. Imaging was performed by CT and X-rays. The minimum craniocaudal diameter at the level of the fracture and the maximum craniocaudal diameter at the middle of the fractured vertebra were measured. Statistical analysis was performed to evaluate pain decrease and height restoration.
RESULTS: Successful implant positioning was achieved in all cases. No major clinical complications were observed. Comparing the mean pain scores at baseline (8.69 ± 1.138) and the first day after the treatment (1.19 ± 1.424), there was a decrease of 7.50 NVS units (p < 0.001). Minimum and maximum vertebral body heights were increased after the procedure 56.58% and 13.7% respectively (p < 0.001). Both pain relief and height restoration remained statistically significant (p < 0.001) during the follow-up period.
CONCLUSION: A2 Magerl thoracic or lumbar fractures could be successfully treated with PEEK implant-assisted vertebral augmentation. Randomized studies with larger sample sizes should be done to confirm the effectiveness of the technique.
KEY POINTS: • Vertebral augmentation using a PEEK implant for the treatment of A2 Magerl lumbar or thoracic vertebral fractures seems to be effective both in terms of pain reduction and height restoration. • Effects on pain reduction and height restoration have a long-term duration. • The technique seems to be safe for the treatment of A2 Magerl fractures, without major complications in our study group.
引用
- Velonakis G, Filippiadis D, Spiliopoulos S, et al. Evaluation of pain reduction and height restoration post vertebral augmentation using a polyether ether ketone (PEEK) polymer implant for the treatment of split (Magerl A2) vertebral fractures: a prospective, long-term, non-randomized study. Eur Radiol. 2018. PMID: 30511178. doi:10.1007/s00330-018-5867-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。